MétaCan
Menu
← Back to cohort

Lessons Learned From a Clinical Trial

2004· review· en· W2136073859 on OpenAlexaff
Paul W. Armstrong, L. Kristin Newby, Christopher B. Granger, Kerry L. Lee, R. J. Simes, Frans Van de Werf, Harvey D. White, Robert M. Califf

Bibliographic record

VenueCirculation · 2004
Typereview
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsAlberta Medical AssociationUniversity of Alberta
Fundersnot available
KeywordsMedicineLibrary scienceFamily medicine

Abstract

fetched live from OpenAlex

R emarkable advances in cardiovascular care have been substantially mediated by large-scale, randomized clinical trials.These trials not only have identified treatments resulting in major improvements in patient outcomes but also have enhanced our understanding of the natural history of contemporary disease and the impact of risk factors and complications.The process by which phase III clinical trials in cardiovascular medicine are created, implemented, completed, analyzed, presented, and published has evolved dramatically over the past decade.Historically, government and academic alliances took center stage in this process because of their intellectual equity, opinion leadership, access to patients, and allocation of public interest-related research tax dollars.This axis has now shifted.Community practitioners and groups of physicians, often organized regionally, now provide the majority of subjects for clinical trials.Furthermore, substantial scientific expertise, at both the basic and clinical levels, resides within multinational pharmaceutical firms.Additionally, contract research organizations have seized the business opportunity afforded by the need for timely and efficient operational aspects of clinical trials.Although communitybased trials, efficiency, and expertise are prerequisites for a major clinical trial, the extraordinary costs of completing them squarely places the sponsor in a dominant position. 1ur participation in the failed large-scale attempt to develop a novel oral glycoprotein IIb/IIIa inhibitor, sibrafiban, for secondary prevention of coronary heart disease has stimulated us to reflect on issues that arose in the design and conduct of this trial. 2,3Using the Sibrafiban Versus Aspirin to Yield Maximum Protection From ischemic Heart Events Post-Acute Coronary Syndromes (SYMPHONY) and 2nd SYMPHONY trials as examples, we review issues here that should be of interest to investigators, clinical practitioners, participating institutions, sponsors, data and safety monitoring boards (DSMBs), and the patients whom we serve. 4Our purpose is to encourage discussion so that standards can be enhanced for this form of collaborative science.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.082
metaresearch head score (Gemma)0.145
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.082
Threshold uncertainty score0.434

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0820.145
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0080.005
Bibliometrics0.0030.003
Science and technology studies0.0010.003
Scholarly communication0.0080.012
Open science0.0050.003
Research integrity0.0090.017
Insufficient payload (model declined to judge)0.0100.003

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.383
GPT teacher head0.480
Teacher spread0.097 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations10
Published2004
Admission routes1
Has abstractyes

Explore more

Same venueCirculation→Same topicDiabetes Treatment and Management→French-language works237,207→